- Home
- IKT vs GLSI Comparison
IKT vs GLSI Comparison
Compare IKT & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- GLSI
- Stock Information
- Founded
- IKT 2008
- GLSI 2006
- Country
- IKT United States
- GLSI United States
- Employees
- IKT N/A
- GLSI N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- IKT Health Care
- GLSI Health Care
- Exchange
- IKT Nasdaq
- GLSI Nasdaq
- Market Cap
- IKT 140.5M
- GLSI 134.6M
- IPO Year
- IKT 2020
- GLSI 2020
- Fundamental
- Price
- IKT $1.94
- GLSI $10.81
- Analyst Decision
- IKT Buy
- GLSI Strong Buy
- Analyst Count
- IKT 2
- GLSI 1
- Target Price
- IKT $8.00
- GLSI $39.00
- AVG Volume (30 Days)
- IKT 529.3K
- GLSI 47.7K
- Earning Date
- IKT 08-13-2025
- GLSI 08-13-2025
- Dividend Yield
- IKT N/A
- GLSI N/A
- EPS Growth
- IKT N/A
- GLSI N/A
- EPS
- IKT N/A
- GLSI N/A
- Revenue
- IKT N/A
- GLSI N/A
- Revenue This Year
- IKT N/A
- GLSI N/A
- Revenue Next Year
- IKT N/A
- GLSI N/A
- P/E Ratio
- IKT N/A
- GLSI N/A
- Revenue Growth
- IKT N/A
- GLSI N/A
- 52 Week Low
- IKT $1.12
- GLSI $8.06
- 52 Week High
- IKT $4.20
- GLSI $17.00
- Technical
- Relative Strength Index (RSI)
- IKT 52.68
- GLSI 67.60
- Support Level
- IKT $1.81
- GLSI $8.97
- Resistance Level
- IKT $2.09
- GLSI $11.52
- Average True Range (ATR)
- IKT 0.14
- GLSI 0.51
- MACD
- IKT 0.02
- GLSI 0.21
- Stochastic Oscillator
- IKT 71.70
- GLSI 75.17
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.